Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.
Radius Health's pricing and reimbursement strategy has been successful, at least with Express Scripts, which included its bone-builder Tymlos on a 2018 formulary that excludes several brand-name drugs.